So… THIS Is Why It Might Be Good Idea — To Solve The Name Confusion — Between US, And German “Mercks”: Bloomberg Still Getting It Wrong.

Don’t misunderstand — Bloomberg is a great news outlet. It has generally very reliable business and law stories, and pharma- ones. [And it may have left some interns in charge of final edits — on videos — on Good Friday afternoon, for all we know.]

But over the at least last 15 years, we’ve documented at least ten or more news outlets (besides Bloomberg and the WSJ) — including the EU-based ones — that have run stories and pictures, and video… referring to the “wrong” Merck… in the outlet’s own story. So too, again — here on Good Friday just passed.

It is crystal clear they mean Rob’s US based firm (with copious references to the PAH biologic approval at FDA this week, no less!) — but the High-Def video open all weekend. . .– but the High-Def video open all weekend… is of the German firm’s HQ, in the gloaming — at… Darmstadt.

By late on Easter Sunday, the editors had corrected the video — but this is precisely why either a settlement or litigation must ensue. People may begin buying the German firm, thinking they get the US powerhouse’s earnings — when in fact, the German firm is now a waif, by comparison. Here’s the corrected link:

…Merck Chair and CEO Robert M. Davis discusses the US approval of Winrevair, a new treatment for a rare, dangerous form of high blood pressure.

Speaking on Bloomberg Television, Davis also comments on Merck’s development of an obesity-fighting drug and health-care costs. (Video edited to remove incorrect graphics)….

Now you know — let’s be careful out there folks… onward, to the Women’s LSU v. Iowa rematch! Grin.

नमस्ते

Leave a comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.